Myeloid Leukemia News and Research

RSS

Myeloid Leukemia is an aggressive (fast-growing) disease in which too many myeloblasts (immature white blood cells that are not lymphoblasts) are found in the bone marrow and blood. Also called acute myeloblastic leukemia, acute myelogenous leukemia, acute nonlymphocytic leukemia, AML, and ANLL.

Young donor age proves critical for survival after stem cell transplantation

The selection of suitable donors is crucial for the long-term recovery of patients after an allogeneic hematopoietic stem cell transplantation (allo-HSCT).

21 Nov 2025

St. Jude scientists identify new therapeutic target for high-risk pediatric leukemia

Acute myeloid leukemia driven by tandem duplications within the UBTF gene (UBTF-TD AML) is a high-risk pediatric cancer in urgent need of novel therapeutic options.

3 Nov 2025

Dysfunction in chromosome-stabilizing protein identified as a cause of deadly illnesses

New research from the University of Wisconsin–Madison reveals that dysfunction in a protein essential to maintaining stability in our chromosomes may be responsible for serious - and sometimes deadly - diseases.

31 Oct 2025

Research shows the potential of structural nanomedicine in cancer treatment

In a promising advance for cancer treatment, Northwestern University scientists have re-engineered the molecular structure of a common chemotherapy drug, making it dramatically more soluble and effective and less toxic.

29 Oct 2025

Scientists discover why a powerful leukemia drug fails in most patients

Researchers from Rutgers Health and other institutions have discovered why a powerful leukemia drug eventually fails in most patients – and found a potential way to overcome that resistance.

17 Oct 2025

Age alone may not predict outcomes in acute myeloid leukemia

An international study conducted by the Alliance for Clinical Trials in Oncology and the Acute Myeloid Leukemia Cooperative Group reveals that age-based classifications in the treatment of acute myeloid leukemia (AML) may be outdated and overly simplistic.

14 Oct 2025

Targeting aggressive childhood leukemia with nanobody PROTACs

Scientists at the University of Duisburg-Essen are researching new therapies for aggressive forms of childhood leukemia.

13 Oct 2025

DKMS advances blood cancer research with groundbreaking ASAP study

The selection of patients for allo-HSCT and the best approach to bridging patients to transplantation is continuously discussed by experts.

6 Oct 2025

Newly discovered mechanism helps leukemia cells to evade the immune system

A research team at Lund University in Sweden has discovered a mechanism that helps acute myeloid leukemia cells to evade the body's immune system.

3 Oct 2025

Analysis shows potential impact of deep NIH budget cuts on future drug development

Gleevec, a cancer drug first approved for sale in 2001, has dramatically changed the lives of people with chronic myeloid leukemia.

25 Sep 2025

The 15th AACR cancer progress report highlights scientific advances

The American Association for Cancer Research (AACR) released the 15th edition of its annual Cancer Progress Report. A cornerstone of the AACR's educational and advocacy efforts, this comprehensive report provides the latest statistics on cancer incidence, mortality, and survivorship and highlights how federal investments in basic, translational, and clinical cancer research and cancer-related population sciences have led to impressive scientific advances that are improving health and saving lives.

17 Sep 2025

New NIH-funded project aims to turn rare HIV cures into broadly applicable immunotherapy

Nearly 20 years ago, a man named Timothy Ray Brown who was living with HIV and cancer, underwent two courses of stem cell transplantation to treat his acute myeloid leukemia.

28 Aug 2025

Natural compound forskolin enhances chemotherapy effectiveness against aggressive leukemia

A natural compound could help fight aggressive leukaemia and amplify the effect of chemotherapy drugs.

26 Aug 2025

Research examines how cancer may invalidate forensic age-estimation tools

Patients with solid tumors, including breast and lung cancers, showed only slightly less accurate results. In contrast, individuals with blood cancers, particularly chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML), sometimes had large errors, with ages overestimated by as much as 50 years.

22 Aug 2025

RUNX1C isoform identified as driver of chemoresistance in acute myeloid leukemia

One of the biggest challenges in cancer treatment is that certain cancers reappear after chemotherapy-and an aggressive type of blood cancer called acute myeloid leukemia (AML) is notorious for this.

17 Aug 2025

Many patients with high-risk myelodysplastic syndromes do not receive guideline-recommended treatment

Most patients with high-risk myelodysplastic syndromes (MDS) do not receive guideline-recommended treatment with hypomethylating agents (HMAs), according to results published in Blood Neoplasia.

6 Aug 2025

Immunotherapy shows promise in changing leukemia’s cellular environment

Scientists studying a hard-to-treat form of blood cancer called acute myeloid leukemia (AML) have found that a type of treatment - immunotherapy - may help change the environment where cancer cells live, possibly helping the immune system respond more effectively.

29 Jul 2025

Discovery of TAF1's role could revolutionize cancer treatment

A new study led by Stephen D. Nimer, M.D., director of Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, shows how a key molecule regulates the generation of new blood cells, a process called hematopoiesis that goes awry in cancer. The findings have the potential to lead to new therapeutic strategies targeting the molecule, a regulator of gene activity called TAF1.

26 Jul 2025

Early-career physician-scientists receive major support from Damon Runyon Cancer Research Foundation

The Damon Runyon Cancer Research Foundation has named five new Damon Runyon Clinical Investigators.

14 Jul 2025

New immunotherapy targets leukemia at its root

Researchers at MUSC Hollings Cancer Center have identified a signaling loop involved in the growth and persistence of leukemia cells – and developed a novel immunotherapy that can disrupt that loop to boost immune function and improve survival.